{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'active versus placebo group in the overall population (AChR-Ab seropositive and', 'AChR-Ab seronegative patients).', 'Total MG-QoL15r score change from Baseline - SEB and TCnB (Visit 1) - to each time', 'point in the active and placebo group.', '4.', 'INVESTIGATIONAL PLAN', '4.1.', 'Summary of Trial Design', 'DESCRIPTION', 'This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 trial to evaluate', 'the efficacy, safety, tolerability, quality of life and impact on normal daily activities of', 'ARGX-113 in patients with gMG.', 'The trial duration is 26 weeks, which consists of:', 'a treatment part where all randomized patients will be treated with IMP, and', 'a re-treatment part where patients may be re-treated with IMP on an \"as needed basis\"', 'during the timeframe of the trial.', 'The trial will include patients on a stable SoC with a total MG-ADL score of > 5 points at', 'Screening and Baseline and with more than 50% of the total score attributed to non-ocular', 'symptoms.', 'The time between Treatment Cycles is based on the duration of the treatment effect and may', 'vary from patient to patient and for each patient from cycle to cycle (patient-tailored', 'approach).', 'SAMPLE SIZE AND STRATIFICATION', 'Approximately 150 patients will be stratified according to 3 stratification factors: Japanese', 'vs. non-Japanese patient, AChR-Ab status (seropositive VS. seronegative) and SoC (patients', 'on NSIDs vs. patients not on NSIDs) and randomized (1:1) within each stratum to be treated', 'with either placebo or ARGX-113, on top of their current SoC. A maximum of 20% of', 'AChR-Ab seronegative patients will be allowed in the trial.', 'Definition: A Japanese patient is defined as a patient whose parents and four grandparents', 'are Japanese, who has the Japanese nationality, was born in Japan, has not lived outside of', 'Japan for a total of > 10 years and currently lives in Japan.', 'TREATMENT CYCLES AND BASELINES', 'The trial will include a Screening period (pre-randomization) of approximately 2 weeks, a', 'first Treatment Cycle and a variable number of subsequent Treatment Cycles administered on', 'an \"as needed basis\". Each Treatment Cycle consists of 9 weekly visits over a period of', 'argenx BVBA', 'Confidential', 'Page 51 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '8 weeks, consisting of a Treatment period of 3 weeks (4 weekly infusions) and a Follow-up', '(FU) period of 5 weeks (see Figure 1). The SEB and the (first) Treatment Cycle Baseline', '(TC[1]B) will both be set at randomization (Visit 1), whilst the Baseline of each subsequent', 'Treatment Cycle (TCnB) will be set at Visit 1 of each corresponding Treatment Cycle.', 'SCREENING AND TREATMENT', \"During the Screening period, patient's eligibility for trial participation will be evaluated.\", 'During the Treatment Cycles, eligible patients will receive, on top of their current SoC and in', 'a blinded fashion, 4 weekly infusions of either 10 mg/kg ARGX-113 or placebo at Visit 1,', 'Visit 2, Visit 3 and Visit 4 of the corresponding Treatment Cycle.', 'STANDARD OF CARE (SoC)', 'Patients should be on a stable dose and frequency of SoC prior to Screening as detailed in', 'Section 4.3.1 (inclusion criterion n\u00b05). Permitted SoC for MG treatment under this protocol', 'include NSIDs (e.g., azathioprine, methotrexate, cyclosporine, tacrolimus, mycophenolate', 'mofetil, and cyclophosphamide), steroids, as well as AChE inhibitors. In case these', 'medications are taken for another indication than MG, same conditions apply.', 'For the entire duration of the trial, a change in the type or dose/regimen of SoC (replacing,', 'adding or removing SoC, or adjustment of the SoC dose and/or frequency) is not allowed.', 'Administration of AChE inhibitors must be halted for at least 12 hours prior to performing', 'the QMG assessment (consistent with the revised manual for the QMG test as recommended', 'by the Myasthenia Gravis Foundation of America Inc [MGFA]) (Barohn 2000). Following', 'this requirement, this possible temporary change in dosing regimen of AChE inhibitors will', 'not be considered as a change in SoC.', 'TIME BETWEEN TREATMENT CYCLES', 'At the end of each Treatment Cycle, patients will enter a variable Inter Treatment Cycle', '(ITC) period during which they will be treated with their SoC only. The length of the ITC', 'period may vary from patient to patient and for each patient from cycle to cycle (patient-', 'tailored approach). The visit frequency in the ITC period is every two weeks, starting 14 days', '(2 days) from the last visit of the previous Treatment Cycle.', 'RE-TREATMENT', 'Each patient will start a new Treatment Cycle with ARGX-113 or placebo when all the', 'following criteria apply (see Appendix 8):', 'The patient has completed the previous Treatment Cycle (i.e. an 8-week time period after', 'first dosing date) AND', 'The patient has a total MG-ADL score of > 5 points with more than 50% of the total', 'score due to non-ocular symptoms AND', 'argenx BVBA', 'Confidential', 'Page 52 of 110']\n\n###\n\n", "completion": "END"}